Last reviewed 2026-04-22 · How we verify

ALVAC-HIV vCP1521 + AIDSVAX

ALVAC-HIV vCP1521 + AIDSVAX is a Therapeutic vaccine Biologic drug developed by U.S. Army Medical Research and Development Command. It is currently in Phase 3 development for HIV-1 prevention in at-risk populations, HIV-1 therapeutic vaccine in chronically infected individuals. Also known as: ALVAC-HIV (vCP1521) >106 CCID50 per 1 mL dose, AIDSVAX® B/E, Bivalent HIV gp120 vaccine subtype B (MN), and E (A244).

A combination HIV vaccine that uses a recombinant canarypox vector (ALVAC-HIV vCP1521) as a prime followed by a recombinant gp120 protein boost (AIDSVAX) to elicit cellular and humoral immune responses against HIV.

A combination HIV vaccine that uses a recombinant canarypox vector (ALVAC-HIV vCP1521) as a prime followed by a recombinant gp120 protein boost (AIDSVAX) to elicit cellular and humoral immune responses against HIV. Used for HIV-1 prevention in at-risk populations, HIV-1 therapeutic vaccine in chronically infected individuals.

At a glance

Mechanism of action

ALVAC-HIV vCP1521 is a recombinant canarypox virus expressing HIV-1 genes that primes the immune system by inducing CD8+ T-cell responses. AIDSVAX is a recombinant gp120 envelope protein that serves as a booster to enhance antibody responses and broaden immune recognition. Together, this prime-boost strategy aims to generate both cell-mediated and humoral immunity to prevent HIV infection or control viral replication.

Approved indications

• HIV-1 prevention in at-risk populations
• HIV-1 therapeutic vaccine in chronically infected individuals

Common side effects

• Injection site reactions (pain, erythema, induration)
• Fever
• Myalgia
• Fatigue

Key clinical trials

• RV630 - Approach to Control HIV With Immune Enhancement and Vaccination (ACHIEV (PHASE1)
• HIV Vaccine in HIV-uninfected Adults (PHASE1)
• A Combination Efficacy Study in Africa of Two DNA-MVA-Env Protein or DNA-Env Protein HIV-1 Vaccine Regimens With PrEP (PHASE2)
• Safety and Immunogenicity of Clade C ALVAC and gp120 HIV Vaccine (PHASE1, PHASE2)
• Pivotal Phase 2b/3 ALVAC/Bivalent gp120/MF59 HIV Vaccine Prevention Safety and Efficacy Study in South Africa (PHASE2, PHASE3)
• Safety and Efficacy of Neutralizing Antibodies and Vaccination for Induction of HIV Remission (PHASE1)
• Study to Evaluate the Safety and Immunogenicity of an Oral HIV Vaccine in Healthy, HIV-uninfected Adults (PHASE1)
• Evaluating the Safety and Immunogenicity of ALVAC-HIV and MF59®- or AS01B-adjuvanted Bivalent Subtype C gp120 in Healthy, HIV-uninfected Adult Participants (PHASE1, PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• ALVAC-HIV vCP1521 + AIDSVAX CI brief — competitive landscape report
• ALVAC-HIV vCP1521 + AIDSVAX updates RSS · CI watch RSS
• U.S. Army Medical Research and Development Command portfolio CI

Frequently asked questions about ALVAC-HIV vCP1521 + AIDSVAX

Related

• Drug class: All Therapeutic vaccine drugs
• Target: All drugs targeting HIV-1 envelope proteins (gp120, gp41)
• Manufacturer: U.S. Army Medical Research and Development Command — full pipeline
• Therapeutic area: All drugs in Immunology / Infectious Disease
• Indication: Drugs for HIV-1 prevention in at-risk populations
• Indication: Drugs for HIV-1 therapeutic vaccine in chronically infected individuals
• Also known as: ALVAC-HIV (vCP1521) >106 CCID50 per 1 mL dose, AIDSVAX® B/E, Bivalent HIV gp120 vaccine subtype B (MN), and E (A244)
• Compare: ALVAC-HIV vCP1521 + AIDSVAX vs similar drugs
• Pricing: ALVAC-HIV vCP1521 + AIDSVAX cost, discount & access